Deadly drug interactions in emergency medicine

Emergency Medicine Clinics of North America

Volumn 22, Issue 4 SPEC. ISS., 2004, Pages 845-863

  Prybys, Katherine M ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b USA ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; ASTEMIZOLE; CELECOXIB; CIMETIDINE; CIPROFLOXACIN; CISAPRIDE; CLARITHROMYCIN; COTRIFAMOLE; DEXTROPROPOXYPHENE; DIGOXIN; DILTIAZEM; DIPHENHYDRAMINE; DISULFIRAM; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; INDINAVIR; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PAROXETINE; PHENOTHIAZINE; PIMOZIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; QUINIDINE; ROFECOXIB; SULFONAMIDE; TERFENADINE; UNINDEXED DRUG; VALDECOXIB; VERAPAMIL; WARFARIN;

BLEEDING TENDENCY; BRAIN HEMORRHAGE; COMA; DIAPHORESIS; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CROSS REACTIVITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FATALITY; DRUG METABOLISM; DRUG MONITORING; DRUG TRANSFORMATION; EMERGENCY MEDICINE; GASTROINTESTINAL HEMORRHAGE; HALLUCINATION; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTHERMIA; HYPOALDOSTERONISM; KIDNEY CLEARANCE; MEDICAL INFORMATION; MULTIPLE ORGAN FAILURE; MYOCLONUS; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; PATIENT INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SEIZURE SUSCEPTIBILITY; SEROTONIN SYNDROME; SINUS TACHYCARDIA; STOMACH BLOOD FLOW; STOMACH CONTENT; STOMACH MOTILITY; STOMACH PH; SUDDEN DEATH;

EID: 5044222542     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.emc.2004.05.001     Document Type: Review

References (101)

1. Kelly W. Potential risks and prevention: Part 1. fatal adverse drug events. Am J Health Sys Pharm. 58:2001;1317-1324
2. Kelly W. Potential risks and prevention: Part 2. drug-induced permanent disabilities. Am J Health Sys Pharm. 58:2001;1325-1329
3. Leape L.L., Brennan T.A., Laird N., Lawthers A.G., Localio A.R., Barnes B.A., et al. The nature of adverse events in hospitalized patients: results of the Harvard medical practice study II. N Engl J Med. 324:1991;377-384
4. Juurlink D.N., Mamdani M., Kopp A., Laupacis A., Redelmeier D.A. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 289:2003;1652-1658
5. Preskorn S. Drug approvals and withdrawals over the last 60 years. J Psychiatr Pract. 8:2002;41-50
6. Berardi R., DeSimone E., Newton G., Oszko M., Popovich N., Rollins C., et al. Handbook of nonprescription drugs. 13th edition :2002;McGraw Hill, New York
7. Figueiras A., Tato F., Fontainas J., Takkouche B., Gestal-Otero J.J. Physicians' attitudes towards voluntary reporting of adverse drug events. J Eval Clin Pract. 7:2001;347-354
8. Chyka P.A., McCommon S.W. Reporting of adverse drug reactions by poison control centres in the US. Drug Saf. 23:2001;87-93
9. ISMP survey shows weaknesses persist in hospital systems for error detection, reporting and analysis. ISMP Medication Safety Alert. 5:(2):2000
10. Gaeta T., Fiorini M., Ender K., Bove J., Diaz J. Potential drug-drug interactions in elderly patients presenting with syncope. J Environ Monit. 22:2002;159-162
11. Kyriacou D.N., Coben J.H. Errors in emergency medicine: research strategies. Acad Emerg Med. 7:2000;1201-1203
12. Goldberg R.M., Mabee J., Chan L., Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 14:1996;447-450
13. Langdorf M.I., Fox J.C., Marwah R.S., Montague B.J., Hart M.M. Physician versus computer knowledge of potential drug interactions in the emergency department. Acad Emerg Med. 7:2000;1321-1329
14. Gaddis G.M., Holt T.R., Woods M. Drug interactions in at-risk emergency department patients. Acad Emerg Med. 9:2002;1162-1167
15. Heininger-Rothbucher D., Bischinger S., Ulmer H., Pechlaner C., Speer G., Wiedermann C.J. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation. 49:2001;283-288
16. Herr R.D., Caravati E.M., Tyler L.S., Lorg E., Linscott M.S. Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med. 21:1992;1331-1336
17. Beers M.H., Storrie M., Lee G. Potential adverse drug interactions in the emergency room. Ann Intern Med. 112:1990;61-64
18. Hancock D., Kennington M.J., Beckner R.R., Quick G. Emergency department medication and drug interaction evaluation. Hosp Pharm. 27:1992;129-132
19. Rosenthal M.B., Berndt E.R., Donohue J.M., Frank R.G., Epstein A.M. Promotion of prescription drugs to consumers. N Engl J Med. 346:2002;498-505
20. Walley T. Lifestyle medicines and the elderly. Drugs Aging. 19:2002;163-168
21. Kelly W. Potential risks and prevention: Part 3. drug-induced threats to life. Am J Health Sys Pharm. 58:2001;1399-1405
22. Esengen S., Seckin U., Borman P., Bodur H., Kutsal Y.G., Yucel M. Drug consumption in a group of elderly residents of a nursing home: relationship of cognitive impairment and disability. J Am Med Dir Assoc. 1:2000;197-201
23. Greene W. Drug interactions involving cimetidine - mechanisms, documentation, implications. Q Rev Drug Metab Drug Interact. 5:1984;25-51
24. Rogers E.A., Gough J.E., Brewer K.L. Are emergency department patients at risk for herb-drug interactions? Acad Emerg Med. 8:2001;932-934
25. Heck A.M., DeWitt B.A., Lukes A.L. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm. 57:2000;1221-1230
26. Miller L. Herbal medicinals. Arch Intern Med. 158:1998;2200-2211
27. Gaeta T., Fiorini M., Ender K., Bove J., Diaz J. Potential drug-drug interactions in elderly patients presenting with syncope. J Environ Monit. 22:2002;159-162
28. Burt C.W., McCraig L.F. Trends in hospital emergency department utilization: United States, 1992-99. National Center for health Statistics. Vital Health Stat. 13:2001;150
29. Gurwitz J.H., Field T.S., Avorn J., McCormick D., Jain S., Eckler M. The incidence and preventability of adverse events in nursing homes. Am J Med. 109:2000;87-94
30. Frank C., Godwin M., Verma S., Kelly A., Birenbaum A., Seguin R., et al. What drugs are our frail elderly patients taking? Do drugs they take or fail to take put them at increased risk of interactions and inappropriate medication use? Can Fam Physician. 47:2001;1198-1204
31. Chung M.K., Bartfield J.M. Knowledge of prescription medications among elderly emergency department patients. Ann Emerg Med. 39:2002;605-608
32. Paauw D.S. Commonly overlooked drug interactions. Emerg Med. 33:(3):2001
33. Reed M.D., Blumer J.L. Drug interactions. Haddad L.M., Shannon M.W., Winchester J.F. Clinical management of poisoning and drug overdose. 3rd edition :1998;307-318 WB Saunders, Philadelphia
34. Delaney K. Biochemical principles. Goldfrank L.R., Flomenbaum N.E., Lewin N.A., Howland M.A., Hoffman R.S., Nelson L.S. Toxicologic emergencies. 7th edition :2002;212-213 McGraw-Hill, New York
35. Drug interactions. Med Lett Drugs Therap. 45:2003;46-48
36. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 38:2000;41-57
37. Chan T.Y. Adverse interactions between warfarin and nonsteroidal anti-inflammatory drugs: mechanism, clinical significance, and avoidance. Ann Pharmacother. 29:1995;1274-1283
38. Preskorn S.H. A message from Titanic. J Pract Psych Behav Health. 4:1998;236-242
39. Friedman M.A., Woodcock J., Lumpkin M.M., Shuren J.E., Hass A.E., Thompson L.J. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 281:1999;1728-1734
40. Jones J.K., Fife D., Curkendall S., Goehring E., Guo J.J., Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA. 286:2001;1607-1609
41. Multidisciplinary Medication Management Project. Top ten dangerous drug interactions in long-term care. Available at: www.amda.com.Accessed August 5, 2003.
42. Lip G.Y., Gibbs C.R. Antiplatelet agent versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM. 95:2002;461-468
43. Cannegieter S.C., Rosendaal F.R., Wintzen A.R., van der Meer F.J.M., Vandenbroucke J.P., Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 333:1995;11-17
44. Freeman M.D., Olatidoye A.G. Clinically significant drug interactions with oral anticoagulants. Drug Saf. 10:1994;381-394
45. Mathiesen T., Benediktsdottir K., Johnsson H., Lindqvist M. Intracranial traumatic and nontraumatic haemorrhagic complications of warfarin treatment. Acta Neurol Scand. 91:1995;208-214
46. Hylek E.M., Heiman H., Skates S.J., et al. Acetaminophen and other risk factors for excessive warfarin anticogaulation. JAMA. 279:1998;657-662
47. Howard P.A., Ellerbeck E.F., Engelman K.K., Patterson K.L. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 11:2002;569-576
48. Panneerselvam S., Baglin C., Lefort W., Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol. 103:1998;422-424
49. Hirri H.M., Green P.J. Audit of anticoagulant therapy and acute hospital admissions. Clin Lab Haematol. 24:2002;43-45
50. Horton J.D., Bushwick B.M. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 59:(3):1999;635-646
51. Byrd D.C., Gaskins S.E., Parrish A.M., Freeman L.B. Warfarin and ciprofloxin interaction: case report and controversy. J Am Board Fam Pract. 12:1999;486-488
52. Renzi R., Finkbeiner S. Ciprofloxin interaction with sodium warfarin: a potentially dangerous side effect. Am J Emerg Med. 9:1991;551-552
53. Jolson H.M., Tanner A., Green L., Grasela T.H. Adverse reaction reporting of interaction between warfarin and fluroquinolones. Arch Intern Med. 151:1991;1003-1004
54. Ellis R.J., Mayo M.S., Bodensteiner D.M. Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol. 63:2000;28-31
55. Bianco T.M., Bussey H.I., Farnett L.E., Linn W.D., Roush M.K., Wong Y.W. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy. 12:1992;435-439
56. Israel D.S., Stotka J., Rock W., Sintek C.D., Kamada A.K., Klein C., et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis. 22:1996;251-256
57. Lehmann D.E. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. Pharmacotherapy. 20:2000;1464-1468
58. Randinitis E.J., Alvey C.W., Koup J.R., Rausch G., Abel R., Bron N.J., et al. Drug interactions with clinafloxacin. Antimicrob Agents Chemother. 45:2001;2543-2552
59. Jones C.B., Fugate S.E. Levofloxacin and warfarin interaction. Ann Pharmacother. 36:2002;1554-1557
60. Ravnan S.L., Locke C. Levofloxacin and warfarin interaction. Pharmacotherapy. 21:2001;884-885
61. Gheno G., Cinetto L. Levofloxacin-warfarin interaction. [letter] Eur J Clin Pharmacol. 57:2001;427
62. Liao S., Palmer M., Fowler C., Nayak R.K. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. J Clin Pharmacol. 36:1996;1072-1077
63. Yamreudeewong W., Lower D.L., Kilpatrick D.M., Enlow A.M., Burrows M.M., Greenwood M.C. Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy. Pharmacotherapy. 23:2003;333-338
64. Artymowicz R.J., Cino B.J., Rossi J.G., Walker J.L., Moore S. Possible interaction between gatifloxin and warfarin. Am J Health Syst Pharm. 59:2002;1205-1206
65. Erichsen C., Sondenaa K., Andersen E., Tysvoer A., Sndenaa K., Sreide J.A. Spontaneous liver hematomas induced by anti-coagulation therapy: A case report and review of the literature. Hepatogastroenterology. 40:1993;402-406
66. Cook D.E., Ponte C.D. Suspected trimethoprim/sulfamethoxazole-induced hypoprothrombinemia. J Fam Pract. 39:1994;589-591
67. Chafin C.C., Ritter B.A., James A., Self T.H. Hospital admission due to warfarin potentiation by TMP-SMX. Nurse Pract. 25:2000;73-75
68. Kaufman J.M., Fauver H.E. Jr. Potentiation of warfarin by trimethoprim-sulfamethoxazole. Urology. 16:1980;601-603
69. Shorr R.I., Ray W.A., Daugherty J.R., et al. Concurrent use of NSAIDs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 153:1993;1665-1670
70. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of anti-inflammatory drugs. N Engl J Med. 340:1999;1888-1899
71. Fitzgerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 345:2001;433-442
72. Stading J.A., Skrabal M.Z., Faulkner M.A. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm. 58:2001;2076-2080
73. Schaefer M.A., Plowman B.K., Morreale A.P., Egan M. Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm. 60:2003;1319-1323
74. Grissinger M. Action needed to avert fatal errors of concomitant use of heparin products. Pharmacy and Therapeutics. 26:2001;462
75. Chambers C.V., Straus W., Diamond J.J., Trapani L.A., Weeks M., Somvanshi N. A cohort study of NSAID use and the management of related gastrointestinal symptoms by primary care patients. Pharmacy and Therapeutics. 28:2003;462-467
76. Sternbach H. The serotonin syndrome. Am J Psychiatry. 148:1991;705-713
77. Mills K.C. Serotonin syndrome: a clinical update. Crit Care Clin. 13:1997;763-783
78. Prior F.H., Isbister G.K., Dawson A.H., Whyte I.M. Serotonin toxicity with therapeutic doses of dexamphetamine and venlafaxine. Med J Aust. 176:2002;240-241
79. Skop B.P., Finkelstein J.A., Mareth T.R., Magoon M.R., Brown T.M. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med. 12:1994;642-644
80. Otte W., Birkenhager T.K., van den Broek W.W. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 18:2003;264-265
81. Karki S.D., Masood G.R. Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmacother. 37:2003;388-391
82. Rengelshausen J., Goggelmann C., Burhenne J., et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol. 56:2003;32-38
83. Xu H., Rashkow A. Clarithromycin-induced digoxin toxicity: a case report and a review of the literature. Conn Med. 65:2001;527-529
84. Pieroni R.E., Marshall J. Fatal digoxin-quinidine interaction in an elderly woman. J Am Geriatr Soc. 29:1981;422-425
85. Ujhelyi M.R. Spotlight article: quinidine enhances digitalis toxicity at therapeutic serum digoxin levels. Heart Lung. 22:1993;560-562
86. Gordon M., Goldenberg L.M. Clinical digoxin toxicity in the aged in association with co-administered verapamil: a report of two cases and review of the literature. J Am Geriatr Soc. 34:1986;659-662
87. Bauersachs J., Fraccarollo D., Ertl G., Gretz N., Wehling M., Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation. 102:2000;2325-2328
88. Johnston R.T., de Bono D.P., Nyman C.R. Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations. Int J Cardiol. 34:1992;213-215
89. Chiu T.F., Bullard M.J., Chen J.C., Liaw S.J., Ng C.J. Rapid life-threatening hyperkalemia after addition of amiloride HCl/ hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med. 30:1997;612-615
90. Wrenger E., Muller R., Moesenthin M., Welte T., Frolich J.C., Neumann K.H. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 327:2003;147-149
91. Schepkens H., Vanholder R., Billiouw J.M., Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 110:2001;438-441
92. Perazella M.A. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 109:2000;307-314
93. Flockhart D.A., Drici M.D., Kerbusch T., Soukhova N., Richard E., Pearle P.L., Mahal S.K., Babb V.J. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 20:2000;317-324
94. McIntyre I.M., King C.V., Staikos V., Gall J., Drummer O.H. A fatality involving moclobemide, sertraline, and pimozide. J Forensic Sci. 42:1997;951-953
95. Krantz M.J., Martell B.A., Arnsten J.H., Gourevitch M.N. Medications that prolong the QT interval. JAMA. 290:2003;1025
96. Granowitz E.V., Tabor K.J., Kirchhoffer J.B. Potentially fatal interaction between azithromycin and disopyramide. Pacing Clin Electrophysiol. 23:2000;1433-1435
97. Preskorn S.H., Silkey B., Jones T. Physician perceptions of drug-drug interactions and how to avoid them. J Psychiatr Pract. 8:2002;112-115
98. Kelly W. Potential risks and prevention: Part 4. reports of significant adverse drug events. Am J Health Syst Pharm. 58:2001;1406-1412
99. Von Ferber L., Koster I., Pruss U. Patient variables with expectations for prescriptions and general practitioners' prescribing behaviour: an observational study. Pharmacoepidemiol Drug Saf. 11:2002;291-299
100. Cohen J.S. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of adverse drug events. Arch Intern Med. 161:2001;957-964
101. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitche S.R., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 348:2003;1425-1434